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ABSTRACT
Objectives: The purpose of this study was to investigate the expression of Filamin b in the placental placenta of patients 
with early or late onset pre-eclampsia (PE) and its potential effects on the pathophysiology of the disease.
Methods and methods: Immunohistochemistry staining, western blot assays and real time PCR were used to detect the 
expression level of FLN-b. The expression levels of MMP-2, MMP-9 and ERK1/2 proteins from control and FLN-b-silenced 
JEG-3 cells were also detected by western blot and JEG-3 cell invasion. 
Results: Compared with normal term pregnancies placentas, the FLN-b expression was significantly lower than that of 
women with PE, its level in late-onset PE is lower than in early-onset PE. In FLN-b-silenced JEG-3 cells, the protein levels of 
MMP-2, MMP-9 and phosphorylated ERK1/2 decreased markedly and the number of cells penetrating through the transwell 
chamber membrane is also greatly reduced. 
Conclusions: Down-regulation of FLN-b inhibits the ERK/MMP-2 and MMP-9 pathways, leading to trophoblastic invasion 
disorders in the PE placenta.
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INTRODUCTION
Pre-eclampsia (PE), which affects 5% to 7% of the world’s 
pregnant women each year, is a pregnancy-specific disease that 
is the leading cause of maternal and neonatal mortality and 
morbidity [1]. The disease is caused by a variety of factors and 
produces undesirable clinical features such as hypertension, 
proteinuria, inflammation, endothelial dysfunction, vasocon-
striction and placental abnormalities [2, 3]. PE can be divided 
into early-onset PE (EPE, < 34 weeks of gestation) and late-onset 
PE (LPE, ≥ 34 weeks of gestation) subtypes. Several pathologi-
cal factors have been proposed to explain the development 
of PE, including inadequate placental development, abnormal 
trophoblast invasion, vascular endothelial dysfunction, oxida-
tive stress, immune maladaptation, exaggerated inflammation 
and genetic involvement. Despite years of ongoing clinical 
research, the etiology and pathogenesis of PE remains unclear. 
Several key aspects of PE can be studied in vitro, but the nature 
of the disease limits the utility of cell culture models. In particu-
lar, PE involves the changes in the behavior of fetal trophoblast 
cells, their interaction with the maternal endothelium, and the 
response of the maternal system to these vascular changes. 
Filamins (FLNs) contain a series of high molecular weight 
cytoskeletal proteins that form a network linked to the surface 
of the cell membrane and play roles in the integration of cel-
lular mechanics and signal transduction [4]. They consist of 
3 isoforms in mammals: FLN-a, FLN-b and FLN-c. The functions 
of FLNs are complex as they regulate the activity of integrins 
and their ligand binding. FLNs also interact with a variety 
of cellular proteins, including transmembrane receptors, ion 
channels, signaling molecules and transcription factors that 
directly or indirectly regulate cellular responses and cellular 
movement [5, 6]. FLN-a, for instance, has been clinically as-
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sociated with the aggressiveness of multiple cancers, includ-
ing hepatic cholangiocarcinoma, pancreatic cancer, prostate 
cancer, metastatic breast cancer and high-grade astrocytoma 
[7–10]. FLN-b suppresses tumor growth and metastasis [11], 
enhances the invasion of cancer cells [12]. FLN-c expression 
is largely restricted to cardiac and skeletal muscle fibers and 
promotes their structural integrity [13]. The aggressive invasion 
of trophoblastic cells in cases of PE is similar to the behavior of 
tumor cells. However, there has been a little research on the 
relationship between the FLN-b and the PE development, its 
expression levels of placental tissues in women between EPE 
and LPE, and its regulatory mechanisms. Proteins of the matrix 
metalloproteinase (MMP) family are involved in the break-
down of extracellular matrix in normal physiological processes, 
Gelatinase-A (MMP-2) and gelatinase-B (MMP-9) participates 
in S1P-evoked follicular ML-1 thyroid cancer cell invasion [14]. 
The MAPK signaling pathway pathway’s general structure 
includes a small G protein (RAS) and three protein kinases (RAF, 
MEK, ERK). The starting point for this pathway is the binding of 
ligand to a transmembrane protein, a receptor tyrosine kinase 
(RTK). The resulting signaling cascade culminates with trans-
location of extracellular signal-regulated kinase ERK (mito-
gen-activated protein kinase, MAPK) to the nucleus, where ERK 
activates transcription factors that result in gene expression 
[15]. Activation or suppression of intracellular signaling via the 
MAPK family has been linked to expression of MMP in experi-
mental models, MMP-2 mRNA expression (P = 0.048), protein 
expression (P = 0.046) and gelatinolytic activity (P = 0.039) 
was positively correlated with ERK phosphorylative activity. 
MMP-2 activity (P = 0.017) and MMP-9 protein expression 
was also correlated with p38 activity and phosphorylation of 
p38 (P = 0.046) [16]. We investigated the expression of FLN-b 
in placentas of the patients with EPE and LPE in addition to its 
pathophysiological effects on PE regarding MMP2, MMP9 and 
MAPK signaling pathway and phospho-ERK (p-ERK).
MATERIAL AND METHODS
Patient information and placenta collection
A written informed consent was obtained from all pa-
tients and the study protocol was approved by the ethics 
committee of the Affiliated Hospital of Qingdao University.
A total of 100 individuals, recruited from September 
2014 to March 2015, were grouped as: 1. The premature de-
livery group (PD, n = 20) included women aged 24–37 years 
with a gestational age < 37 weeks without other compli-
cations; 2. The normal singleton term pregnancies group 
(STP, n = 20); 3. The early gestation group (EG, n = 20), included 
healthy women undergoing legal abortion for nonmedical 
reasons; 4. The Preeclampsia group (PE), included 40 women 
with PE aged 25–44 years. The diagnosis of the PE was based 
on clinical evidence. According to onset time as defined in 
the introduction above, they were further divided into two 
subgroups: EPE (n = 20), and LPE (n = 20) (Tab. 1). Smoking, 
women with chronic hypertension, alcohol consumption, 
women with eclampsia or gestational diabetes, and women 
with multiple pregnancies were excluded from the study. 
The placentas were collected immediately after vagi-
nal or Cesarean section delivery under aseptic condi-
tions. After removing the decidual layer, the placenta tis-
sues (1.0 cm3 each X 3) were washed 5 times in ice cold 
phosphate-buffered saline (PBS) to remove blood. 
Cell line
The JEG-3 cells was acquired from the cell bank at the 
Chinese Academy of Sciences (Shanghai, P. R. China) and 
cultured in minimum essential medium (MEM, Gibco,USA), 
containing 10% (v/v) fetal bovine serum (HyClone/GE 
Healthcare, Chicago, IL, USA), and 1% penicillin/strepto-
mycin (Gibco), incubated at 37°C in a humidified atmosphere 
of 5% CO2. Cells (10
5/mL) were seeded in 6-well plates for 
30%–50% confluence at the time of transfection. Transfec-
tion using 50 nM short interfering FLN-b-siRNA and incu-
bated for 72 h to suppress native FLN-b expression was 
performed according to the manufacturer’s instructions 
(Ribobio Life Technologies, Guangzhou, P. R. China), control 
cells were treated with the same volume of sterile PBS.
Immunohistochemistry (IHC) staining
The streptavidin–biotin–peroxidase complex method was 
used for IHC staining for all paraffin-embedded placental tis-
sues. Sections (5-mm thick) were prepared and incubated with 
a primary antibody to FLN-b (1:150, Rabbit anti human mono-
Table 1. The demographic and clinical characteristics of the five groups (Mean ± SD)
Characteristics Premature delivery
Normal singleton 
term pregnancies
Early 
gestation
Early 
onset PE
Late
onset PE P-value
Maternal [years] 27.14 ± 2.96 28.52 ± 3.85 27.82 ± 2.43 29.43 ± 3.69 29.32 ± 2.92 0.0762
Times of gravidity 2.17 ± 0.98 3.01 ± 1.84 2.32 ± 1.08 2.85 ± 1.57 2.69 ± 1.32 0.1481
Gestational age [weeks] 32.58 ± 3.36* 38.73 ± 4.28 8.5 ± 1.32* 33.49 ± 2.83* 37.95 ± 2.66 < 0.001
Systolic blood pressure [mmHg] 120.65 ± 17.47 123.69 ± 14.70 128.53 ± 12.44 153.39 ± 13.72* 158.74 ± 18.84* < 0.001
Diastolic blood pressure [mmHg] 71.95 ± 6.72 73.41 ± 7.85 76.49 ± 8.55 113.58 ± 9.8* 103.74 ± 13.79* < 0.001
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clonal antibody; Sigma-Aldrich, St Louis, MO, USA) overnight at 
4°C, then washed in PBS three times for 5 min each, incubated 
with a secondary antibody (Gene Tech, Shanghai, China) for 
30 min at 37°C. The sections were washed again three times 
with PBS. 3, 3´aminobenzidine (CW-BIO, Beijing, P. R. China) 
was used as the chromogen and hematoxylin (Sigma-Aldrich) 
was used as a nuclear counterstain.
RT–qPCR 
The expression levels of FLNb mRNA were detected 
using RT–qPCR. Total RNA was extracted from placental 
tissues using TRIzol protocol (Invitrogen Life Sciences, 
Carlsbad, CA, USA) and purified according to the manufac-
turer’s instructions. 2µg of RNA were reverse transcribed 
in a 20-mL reaction volume containing Superscript II re-
verse transcriptase (Invitrogen Life Sciences), incubated 
for 50 min at 42°C, then for 15 min at 72°C. The qPCR was 
performed using TaKaRa SYBR Premix Ex Taq II kits (TaKaRa, 
Otsu, Japan) on an ABI Prism 7500 Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA) in triplicate in 
25 -µL volumes: Aliquots of 2 mL of cDNA were mixed with 
1.6 mL primers, 10 mL SYBR Premix Ex Taq II and 0.4 µL ROX 
Reference Dye II. The PCR program was initiated at 95°C 
for 30 s, followed by 40 cycles at 95°C for 5 s and annealing 
and extension at 60°C for 34 s. A melting curve for primer 
validation and a template standard curve were generated 
to confirm template-independent amplification. Relative 
mRNA levels were calculated by using the 2–DDCt method 
against the normalized b-actin. The PCR primers used were:
FLN-b: Forward, 5´–CAAATAACGGACCAAGAAGGA–3´; 
Reverse, 5´–C CGATAAGGAGAAAGTGGGATGT–3´
b-actin: Forward, 5´–ATAGTTGCGTTACACCCTTTCTTG–3 
Reverse, 5´–TCACCTTCACCGTTCCAGTTT–3´.
Western blotting
Placental tissues: the fresh frozen tissues were homoge-
nized in 20 mM Tris (pH 7.4), 137 mM NaCl, 2 mM ethylenedi-
aminetetraacetic acid (EDTA), 1 mM phenylmethanesulfonyl 
fluoride (PMSF), 1% Triton-X 100, 20 mM leupeptin, 10% 
glycerol, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxy-
cholate and 5 mg/mL aprotinin. 
JEG-3 cells: JEG-3 cells were washed in PBS for 
3 times. Proteins from  tissues and JEG-3 cells were extracted 
using RIPA/PMSF (100:1) solution according to the manufac-
turer’s instructions. 50 µg protein was electro-separated on 
a 10% SDS-PAGE gel and electro-transferred onto a polyvi-
nylidene difluoride membrane (Millipore, Bedford, MA, USA) 
for Western blotting. After being blocked with 5% skim milk 
for 1 h at room temperature, the PVDF membranes were 
incubated sequentially with primary antibodies (1: 2000, 
Abcam, Cambridge, MA, USA) against FLN-b, MMP2, MMP9, 
ERK1/2, PERK, and GAPDH (1:2500; Abcam) overnight at 4°C, 
and then washed three times for 10 min each by 1 × TBST 
(Tris-Buffered Saline with Tween 20). A subsequent incu-
bation with a goat anti-rabbit HRP antibody (Abcam) was 
carried out for 1 h at room temperature in 5% skim milk, and 
three washes with TBST were carried out. Finally, enhanced 
chemiluminescence detection substrate was used to pro-
cess the PVDF membranes (Pierce Chemical Co., Rockford, 
IL, USA). The image was analyzed using ChemiScope mini 
chemiluminescence meter to calculate the optical density of 
the target and the internal control band for the protein ex-
pression. Protein expression = integral optical density value 
of target protein/integral optical density value of GAPDH.
Transwell assay
Cell invasion assays were performed using transwell 
chambers precoated with Matrigel (BD Biosciences, Franklin 
Lakes, NJ, USA). The lower chamber contained MEM with 10% 
FBS. The JEG-3 cells were pre-cultured with or without FLN-b 
siRNA (50 nM) about 72h. Then they were washed three times 
with PBS for 10 min and suspended in MEM, added 200 mL 
cell suspension (1 × 105 cells/mL) to the upper chamber 
and incubated for 24 h at 37°C. The upper chamber cells 
that did not invade through the membrane were wiped out 
using a sterile cotton-tipped swab. The filters were fixed in 
methanol and stained with 4´, 6-diamidino-2-phenylindole 
(DAPI). The numbers of invasived cells with nuclei stained 
DAPI were counted under fluorescence microscopy.
Statistical analysis
At least three replications were done for each experi-
ment. Data (mean ± SD) were analyzed by Student–New-
man–Keuls multiple comparison tests and independent 
t tests using Graph-Pad Prism software (v. 5; La Jolla, CA, 
USA). Differences at p < 0.05 were considered statistically 
significant.
RESULTS
Localization and expression of FLN-b  
in placentas
IHC showed (Fig. 1A) FLN-b was mainly expressed in the 
cytoplasm of trophoblasts and placental capillary endothe-
lial cells. FLN-b expression in the placenta collected during 
PD, STP and EG was significantly higher, but it was declined 
in the placenta of PE (Fig. 1B).
RT–qPCR data (Fig.1C) indicated that the level of 
FLN-b mRNA in placentas of the EPE (0.80 ± 0.12) and LPE 
(0.67 ± 0.09) was significantly lower than that of the EG 
(1.61 ± 0.07), STP (1.07 ± 0.06), and PD (1.32 ± 0.09) groups 
(p < 0.05). The expression of FLN-b mRNA in the EPE placenta 
(0.80 ± 0.12) was higher than in LPE (0.67 ± 0.09).
The level of FLN-b protein in placentas of the LPE 
(0.64 ± 0.07) and of the EPE (0.82 ± 0.05) was significantly 
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lower than that of the EG (2.14 ± 0.09), STP (1.03 ± 0.03), 
and PD groups (1.18 ± 0.08) (p < 0.05). Although the expres-
sion of FLN-b decreased significantly in both EPE and LPE 
groups, the expression of FLN-b in the EPE placenta (Fig. 1D, 
0.82 ± 0.05) was significantly higher than in the LPE placenta 
(Fig. 1E, 0.64 ± 0.07). 
Depletion of FLN-b decreased the invasion rate 
in JEG-3 cells
Figure 2A presented that FLN-b mRNA relative expres-
sion level decreased in the FLN-b-silenced cells (0.39 ± 0.01) 
was compared with control cells (1.00 ± 0.03). Western 
blot analysis also confirmed that an FLN-b protein level in 
Figure 1. Expression of FLN-b in placental villi by immunohistochemistry (400 X) A — The representative images of FLN-b expression in human  
placentas tissue: a. Pretmature delivery; b. Term delivery; c. Early gestation; d. Early onset PE; e. Late onset PE; the black arrows indicated the positive 
staining; B — FLN-b average optical density assay of immunohistochemistry staining (Western bolting) and its statistical analysis (mean ± SD); *P < 0.05
2500
2000
1500
1000
500
0
2.0
1.5
1.0
0.5
0
2.5
2.0
1.5
1.0
0.5
0
A
ve
ra
ge
 o
pt
ic
al
 d
en
si
ty
Re
la
tiv
e 
FL
N
-b
 m
RN
A
 le
ve
l
Re
la
tiv
e 
FL
N
-b
 p
ro
te
in
 le
ve
l
GAPDH (36kDa)
FLN-b (278kDa)
D
B
A
C
E
a b c d e a b c d e
a b c d e
a b c d e
a b c d e
1.5
1.0
0.5
0
Re
la
tiv
e 
FL
N
-b
 m
RN
A
 le
ve
l
GAPDH (36kDa)
FLN-b (278kDa)
B
A
siRNAControl
Control siRNA
Figure 2. Relative expression of FLN-b in the control and FLN-b silenced JEG-3 cells. A — mRNA; B — FLN-b protein level
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FLN-b-silenced JEG-3 cells (53.42 ± 0.96) was significantly 
lower than that of the control cells (97.38 ± 0.85) (Fig. 2B). 
Transwell assay results showed that the FLN-b-silenced 
JEG-3 cell numbers (22.00 ± 2.31%) penetrated through 
the membrane were decreased significantly compared 
with the control (41.33 ± 4.10%) (Fig. 3), suggesting that 
blocking FLN-b production reduced the invasive ability of 
in FLN-b-silenced JEG-3 cells.
Depletion of FLN-b decreased MMP2, MMP9 and 
p-ERK expression levels in JEG-3 cells
To further explore the effect of FLN-b and its concen-
tration changes on JEG-3 cells, we measured the MMP-2, 
MMP-9 protein p-ERK and ERK levels by Western blotting. The 
expression levels of FLN-b (61 ± 0.01), MMP-2 (71.37 ± 0.02), 
MMP-9 (72.14 ± 1.06), p-ERK (72.41 ± 1.58) in FLN-b-silenced 
JEG-3 cells were significantly decreased as compared to 
the control group (Fig. 4B to Fig. 4E, p < 0.05), but there 
was no difference in the expression of total ERK between 
FLN-b-silenced JEG-3 cells (75.83 ± 2.27) and the control 
group (99.00 ± 0.56). (Fig. 4F, p > 0.05)However, there was 
a decrease in the level of phosphorylated ERK1 (44kDa, 
Thr202/Tyr204) and of phosphorylated ERK2 (42kDa, 
Thr185/Tyr187) in FLN-b-silenced JEG-3 cells as compared 
to the control (Fig. 4E, P < 0.05), indicating that MAPK signal-
ing pathway has been implicated in these process. 
DISCUSSION
PE is a systemic complication of pregnancy associated 
with high risks of preterm delivery, intrauterine growth 
restriction, placental abruption and perinatal mortality. 
Therefore, it is important to look for the reasons of PE. In 
this study, we explored the localization patterns, expres-
sion and potential roles of FLN-b in placentas from different 
groups and found that silencing FLN-b by siRNA reduced 
the invasive ability of JEG-3 cells and it was associated with 
a significant decrease in MMP2, MMP9 and p-ERK expression. 
Exogenous trophoblast invasion is associated with embryo 
implantation and placental formation. If this invasion is sup-
pressed, the subsequent placental dysfunction can lead to 
various obstetric diseases, such as PE. The mechanisms of 
invasion of trophoblast cells are similar to those of tumor 
cells. Thus, FLN-b expression suppresses tumor growth and 
metastasis and enhances the invasion of cancer cells [11]. 
However, the function of FLN-b in of PE has barely been 
explored. Using IHC, RT–qPCR and western blotting tech-
niques, we compared the distribution and expression of 
FLN-b in placentas derived from women with EG, STP, PD, 
EPE and LPE. 
In this study JEG-3 cells, a trophoblast invasion model, 
was used to study to the role of FLN-b in PE assessed using 
cell motility and migration as well as the effect of FLN-b-si-
lenced cells on trophoblastic invasion. Our results indicated 
that the invasion of FLN-b in siRNA-treated cells was reduced 
significantly. The invasion mechanism of trophoblast cells 
is complex and involves many molecules, including cell 
growth, adhesion, differentiation, and degradation of the 
extracellular matrix (ECM). The precise molecular mecha-
nisms that regulate trophoblast invasion during gestation 
and its relationship to the placental development are largely 
unknown, but several proteinases, cytokines, and growth 
factors appear to be involved. MMPs are metal-dependent 
endopeptidases capable of degrading extracellular matrix. 
MMPs and their regulators, including tissue inhibitors of 
metalloproteinase (TIMPs), appear to play a critical role in 
mediating trophoblast invasion [17–20]. The degradation of 
ECM is thought to contribute to the invasion of trophoblast 
cells into the endometrium [21]. It has been reported that 
the key protein hydrolase in the trophoblast invasion is 
the MMP family. MMP-2 is the most important enzymes for 
the degradation of type IV collagen. The MMP-9 has been 
identified as a trophoblast-derived MMP [22]. 
By either directly modulating the actin cytoskeleton or 
scaffolding for other signaling molecules, FLNs are widely 
recognized as critical factor for the cell motility. FLN-a de-
ficient human melanoma cells and FLN-b−/− MEFs show 
significantly reduced cell migration. FLN-b−/− tumor cells 
also displayed enhanced invasive capability in vitro [23]. 
50
40
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20
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siRNAControl
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Figure 3. Effects of FLN-b on invasion of JEG-3cell. The number of invasive cells whose nuclei were stained was counted under fluorescence 
microscopic. The left pictures showed the nuclei of the invasive cells and the right picture showed statistical analysis of the number of invasive 
cells. *P < 0.05 versus control
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However, Bandaru et al. found that the increased invasion 
capability in vitro and the enhanced metastasis in vivo of 
FLN-b-deficient tumor cells may be mediated by MMP-9 ex-
pression regulated by the MAPK / ERK cascade [24].
Our results showed that FLN-b was expressed in all of the 
normal term and PE groups. Most of the expression was locat-
ed in the cytoplasm of trophoblastic and placental capillary 
endothelial cells. The IHC staining levels of FLN-b in the PE pla-
centas were lower than that in the normal gestation placental 
tissues. These results are consistent with those of Bandaru 
et al. [11] which suggested a differential role of FLN-b in tumor 
progression may also be seen in PE. In addition, the expression 
of FLN-b mRNA and protein levels were reduced in the placen-
tas in the women with EPE as compared to LPE. The expression 
of FLN-b in EPE and LPE were lower than that of women with 
PD, STP and EG. The depletion of FLN-b was associated with 
the decreased MMP-2 and MMP-9 expression. The activation 
of MMP is mainly regulated by the ERK1/2 phosphorylation 
pathway [25]. We observed that the total ERK1/2 level had no 
discernible difference between the FLN-b-silenced cells and 
control groups, whereas the p-ERK1/2 level showed a sig-
nificant decrease in the FLN-b-silenced cells. This indicated 
that the low expression of MMP-2 and MMP-9 with FLN-b 
depletion may attribute to the p-ERK1/2 signal transduc-
tion pathway and its downstream effect, resulting in the 
decreased invasion of trophoblastic cells. Thus, FLN-b is likely 
to be functioned through the p-ERK1/2 signaling pathway to 
upregulate the MMP-2 and MMP-9 expression levels during 
trophoblast invasion.
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